医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Praxair Starts up New Air Separation Plant in Korea

2013年07月16日 PM10:25
このエントリーをはてなブックマークに追加


 

DANBURY, Conn. & HWASUNG, Korea

Praxair Korea, a subsidiary of Praxair, Inc. (NYSE: PX), announced the start-up of its second state-of-the-art air separation plant at the Samsung Electronics Co., Ltd. (Samsung) semiconductor facility in Hwasung, Korea. Through a long-term contract, the plant will supply on-site high-purity oxygen, nitrogen and argon to Samsung, one of the largest electronics companies in the world and the largest global producer of memory chips, TFT-LCDs, CDMA mobile phones and monitors.

The air separation plant will also expand Praxair’s merchant capacity in the region, supplying liquid oxygen, nitrogen and argon to a variety of industries, including non-ferrous metal, wastewater treatment and shipbuilding. In addition to atmospheric gases, Praxair supplies hydrogen, helium, process gases, sputtering targets, ALD precursors and other advanced materials for use in Samsung’s manufacturing processes.

“Praxair Korea is proud to be the largest atmospheric gases supplier to Samsung,” said S.B. Seo, president of Praxair Korea. “Praxair Korea has worked successfully with Samsung for more than 20 years, increasing the supply of gases to the company’s main manufacturing complexes in the country and supporting the company’s global growth and leadership position in the semiconductors and consumer electronics industries.”

About Praxair

Praxair, Inc. is the largest industrial gases company in North and South America, and one of the largest worldwide, with 2012 sales of $11 billion. The company produces, sells and distributes atmospheric, process and specialty gases, and high-performance surface coatings. Praxair products, services and technologies are making our planet more productive by bringing efficiency and environmental benefits to a wide variety of industries, including aerospace, chemicals, food and beverage, electronics, energy, healthcare, manufacturing, metals and others. More information about Praxair, Inc. is available at www.praxair.com.

CONTACT

Praxair, Inc.
Media:
Lisa Esneault,
203-837-2671
lisa_esneault@praxair.com
or
Investor:
Kelcey
Hoyt, 203-837-2118
kelcey_hoyt@praxair.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • サラダックス・バイオメディカル、サルバトーレ・J・サラモネ博士が権威ある C.E. Pippenger博士賞を受賞したと発表
  • Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
  • VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan
  • TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
  • New Study Evaluates the Feasibility of Using Masimo EMMA® Capnography on Mechanically Ventilated Neonates